A -- IN-VIVO EFFICACY IN DISEASE-RELATED MODELS

Notice Date

September 25, 2001

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Room 604, Rockville, MD, 20852

ZIP Code

20852

Solicitation Number

N01-CM-97017

Response Due

October 31, 2001

Point of Contact

MaryAnne Golling, Contracting Officer, Phone (301) 435-3819, Fax (301) 402-6699, Email mg345x@nih.gov -- Nancy Coleman, Contracting Officer, Phone (301) 435-3820, Fax (301) 402-6699, Email nc31y@nih.gov

Description

POTENTIAL OFFERORS WILL BE RESPONSIBLE FOR DOWNLOADING THEIR OWN COPY OF THE SOLICITATION AND ANY AMENDMENTS. The Developmental Therapeutics Program (DTP) is interested in establishing a Master Agreement (MA) pool. The MA award is non-monetary. Contractors selected for award of a MA may be solicited to address the following objectives. First, to define the capacity of candidate compounds to affect molecular targets relatable to compound efficacy in a series of pre-existing, robust, in vivo models suitable for immediate use, representing known important pathways in neoplasia; second, to validate methodologies that would assess molecular targets affected by drug candidates which could be readily translated to clinical settings; and third, place these actions of the compound in the context of conventional measures of tumor shrinkage or growth delay. Following the identification of appropriate drug leads, and taking into account previously established pharmacologic and biologic features of the test molecules, study in an in vivo model will be undertaken to define not only effects on cell proliferation as an endpoint, but also effects of the drug on its putative molecular target or cellular process of reference. Examples might include models engineered to be relevant to cell cycle checkpoint control (e.g., Rb, 53), apoptosis (e.g., bc12 family genes), molecularly defined but cell type-related (e.g. mutated androgen receptor in prostate cancer) or process-related (e.g., angiogenesis, endocytosis, cell motility, etc.) disease endpoints. Spontaneous, genetically modified or induced (e.g. knockout), orthotopic and xenotransplanted models are all of potential interest, provided that their biological characteristics and correlation with relevant issues in the pathogenesis of neoplasia are clearly apparent. The results of a project area supported by this MA would be evident that a candidate compound could indeed affect a clearly defined molecular endpoint. This information would be of critical importance in designing initial activates where the endpoint of the compound's action may not be classical cytoxic effect, but for example cytostasis or differentiation. This activity would support a new way of thinking about cancer drug action, which has modulation of important molecular targets or cellular processes as endpoints for early clinical trials. MA will be awarded to all respondents whose technical proposal is considered acceptable. THE MA AWARD IS NON-MONETARY and is exclusively for the purpose of compiling a pool of contractors who are ore-qualified to perform services. This acquisition is for the remaining three years Master Pool in support of the Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute located in Rockville, Maryland. Each MA holder will be eligible to compete for future contract awards to carry out specific tasks. MA holders receiving a contract will be selected through this pool, based on technical merit and on budgetary considerations for the specified task involved. The MA mechanism is a pre-qualification to enable qualified sources to compete for and perform future contracts, which will be awarded, based on Requests for Proposal (RFPs). The obligation of funds shall be accomplished solely through the award of a contract. All responsible sources meeting these criteria are encouraged to submit a proposal and will be considered by the NCI. All proposals should reference N01-CM-97017-54. The RFP may be accessed through the Research Contracts Branch Home Page by using the following address: http://amb.nci.nih.gov/. IT IS THE OFFEROR'S RESPONSIBILITY TO MONITOR THE ABOVE SITE FOR THE RELEASE OF SOLICITATIONS AND AMENDMENTS, IF ANY. Those offerors already included in this pool need not respond. No collect calls will be accepted.

Web Link

Visit this URL for the latest information about this (http://www.eps.gov/spg/HHS/NIH/RCB/N01-CM-97017/listing.html)

Record

Loren Data Corp. 20010927/ASOL001.HTM (D-268 SN50Y6G3)